Lung volume reduction surgery since the National Emphysema Treatment Trial: Study of Society of Thoracic Surgeons Database  by Decker, Marquita R. et al.
GENERALTHORACIC SURGERYLung volume reduction surgery since the National Emphysema
Treatment Trial: Study of Society of Thoracic Surgeons DatabaseMarquita R. Decker, MD, MPH,a Glen E. Leverson, PhD,a Wassim Abi Jaoude, MD,b and
James D. Maloney, MDa,bFrom th
Univ
Depa
Funding
Surgi
Disclos
Read in
Geor
Receive
publi
Address
Scien
0022-52
Copyrig
http://dx
G
T
SObjectives: The National Emphysema Treatment Trial demonstrated that lung volume reduction surgery is an
effective treatment for emphysema in select patients. With chronic lower respiratory disease being the third
leading cause of death in the United States, this study sought to assess practice patterns and outcomes for
lung volume reduction surgery on a national level since the National Emphysema Treatment Trial.
Methods: Aggregate statistics on lung volume reduction surgery reported in the Society of Thoracic Surgeons
Database from January 2003 to June 2011 were analyzed to assess procedure volume, preoperative and operative
characteristics, and outcomes. Comparisons with published data from the National Emphysema Treatment Trial
were made using chi-square and 2-sided t tests.
Results: In 8.5 years, 538 patients underwent lung volume reduction surgery, with 20 to 118 cases reported in the
Society of Thoracic SurgeonsDatabase per year.When comparedwith subjects in theNational EmphysemaTreat-
ment Trial, subjects in the Society of Thoracic Surgeons Database were younger (P<.001), a larger proportion
underwent the procedure thoracoscopically (P<.001), and forced expiratory volume in 1 secondwas 31% versus
28% of predicted (P<.001).Whenmortality was compared between subjects in the Society of Thoracic Surgeons
Database and all subjects in the National Emphysema Treatment Trial randomized to surgery, there were no sig-
nificant differences. However, mortality was 3% higher in subjects in the Society of Thoracic Surgeons Database
when compared with the non–high-risk National Emphysema Treatment Trial subset (P ¼ .005).
Conclusions: This study demonstrates the importance of patient selection and the need to develop consensus on
appropriate benchmarks for mortality rates after lung volume reduction surgery. It underscores the need for
dedicated centers to increasingly address the heavy burden of chronic lower respiratory disease in the United
States in a multidisciplinary fashion, particularly for preoperative evaluation and postoperative management
of emphysema. (J Thorac Cardiovasc Surg 2014;148:2651-8)Supplemental material is available online.
Chronic lower respiratory disease is the third leading
cause of death in the United States,1 with chronic
obstructive pulmonary disease (COPD) taking approxi-
mately 126,000 lives every year.2 At least one third of
these COPD cases are related to a diagnosis of emphy-
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The Journal of Thoracic and Carinclude oxygen therapy, beta agonists and anti-
cholinergics, oral and inhaled steroids, pulmonary reha-
bilitation, lung transplantation, experimental endobron-
chial therapies, and lung volume reduction surgery
(LVRS). LVRS has been reported to improve long-term
survival and quality of life in appropriately selected pa-
tients with emphysema,4-9 but LVRS practice patterns
and outcomes have not since been evaluated nationally,
outside of a clinical trial.
The National Emphysema Treatment Trial (NETT),4,5
which first published results in 2003, randomized 1218
patients with emphysema to LVRS or best medical
therapy and examined the primary end points of
survival and maximal exercise performance, with
secondary end points of pulmonary function, patient
symptom severity, and quality of life.4 The NETT had
a large enough subject enrollment to identify the sub-
group of patients with emphysema with heterogeneous,
upper lobe predominant disease, and low exercise capac-
ity who have the best short- and long-term outcomes af-
ter bilateral LVRS, with significant improvements in
survival and exercise capacity. The trial also identified
that people with a forced expiratory volume in 1 seconddiovascular Surgery c Volume 148, Number 6 2651
Abbreviations and Acronyms
CMS ¼ Centers for Medicare &Medicaid Services
COPD ¼ chronic obstructive pulmonary disease
LVRS ¼ lung volume reduction surgery
NETT ¼ National Emphysema Treatment Trial
STS ¼ Society of Thoracic Surgeons
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Sof 20% or less than predicted and those with a homoge-
neous distribution of emphysema or carbon monoxide
diffusing capacity of 20% or less than predicted were
at high risk of death after LVRS.4 The NETT thus
defined selection criteria for patients with emphysema
who are appropriate candidates for LVRS by identifying
those who are at high risk for poor outcomes. Since
closure of the trial, multiple meta-analyses of LVRS
outcomes have been performed using NETT data, but
there have been few subsequent studies reporting
LVRS outcomes in the post-NETT era. Approximately
10 years after the trial results were published, it is
worthwhile to evaluate LVRS practice patterns and out-
comes on a national level.
Despite the published benefits of LVRS as a treatment op-
tion for emphysema, the procedure is reportedly under-
used.10 Reasons for this are unclear, because COPD and
emphysema comprise a significant burden of disease in
the US population. The National Heart, Lung, and Blood
Institute projected that COPD costs $29.6 billion in direct
healthcare expenditures and $20.4 billion in indirect
morbidity and mortality expenditures annually.11 In this
study, we report on comprehensive LVRS data from the
Society of Thoracic Surgeons (STS) Database beginning
in 2003, when the NETTwas first published. The STS Data-
base provides a geographically diverse national sample,
which unlike Medicare claims data, includes patients aged
less than 65 years. This is a valuable advantage of STS
data because approximately half of patients with emphy-
sema in the country are aged 45 to 64 years.2 By examining
the outcomes of LVRS in the STS Database and comparing
outcomes with results of the NETT, our study assesses the
performance of LVRS compared with the clinical bench-
mark set by a landmark clinical trial. This study has impli-
cations for future identification of determinants of LVRS
quality and development of LVRS-specific quality
benchmarks.MATERIALS AND METHODS
Study Design and Data Sources
This study involved a retrospective review of de-identified aggregate
statistics on patients who underwent LVRS reported in the STS Database
from 2003 to 2011. Previously published data from the NETT4,5,12,13
were studied for statistical comparison. The University of Wisconsin
Institutional Review Board approved this study.2652 The Journal of Thoracic and Cardiovascular SurStudy Populations
Subjects in the NETT who were randomized to surgery underwent
bilateral stapled wedge resection. These patients were subdivided into a
non–high-risk group and a subgroup of non–high-risk patients with upper
lobe predominant disease and low exercise tolerance.
Patients included in the analysis of patients in the STS Database under-
went bilateral or unilateral resection. Both groups were included because of
the lack of distinction between unilateral and bilateral LVRS in certain
versions of the STS General Thoracic Surgery Database Major Procedure
Collection Form.14 Patients with the following procedure codes were
included:
Major Procedure Collection Form Version 2.2 (Last revised 2012):
‘‘Removal of lung, excision-plication of emphysematous lung(s) for lung
volume reduction (LVRS) (32491)’’; ‘‘Thoracoscopy with resectionplica-
tion for emphysematous lung (bullous or non-bullous) for lung volume
reduction-LVRS, unilateral including any pleural procedure (32672).’’
Version 2.081 (Last revised 2009): ‘‘Removal of lung, excision-plication
of emphysematous lung(s) for lung volume reduction (LVRS) (32491).’’
Versions 2.06 (2004) and 2.07 (2005): ‘‘Lung volume reduction.’’
Analysis
The STS Database yearly annual volume of LVRS was calculated to
depict nationwide trends in volume over time, without attempt to capture
total national volume. Meta-analysis was required to estimate differences
between sample means and proportions using null hypothesis significance
testing with t tests and chi-square tests, respectively. This allowed for
estimation of confidence intervals around calculated differences in event
rates, while accounting for sample size. Confidence intervals around
estimated differences were calculated using the Z statistic, with
alpha ¼ 0.05, assuming normal distribution. Preoperative and operative
characteristics were compared between patients in the STS Database
who underwent LVRS and patients in the NETT who were randomized
to surgery. Preoperative characteristics included age, sex, race, and pulmo-
nary function tests, which included percent of predicted forced expiratory
volume in 1 second and carbon monoxide diffusing capacity. Operative
characteristics accounted for the surgical approach to lung volume reduc-
tion: median sternotomy, video-assisted thoracoscopic surgery, or other.
Descriptive statistics on health status indicators and comorbidities of
patients in the STS Database were calculated. Published data on the overall
health status and comorbidities of subjects in the NETT were not directly
comparable. Therefore, a descriptive comparison was made on the basis
of related health indicators and NETT cohort selection criteria. STS health
status indicators and comorbidities included congestive heart failure,
coronary artery disease, pulmonary hypertension, systemic hypertension,
peripheral vascular disease, diabetes, steroid use (defined as systemic
steroid therapy, inhaled steroid therapy, or preoperative protocol within
30 days before the procedure),14 previous cardiothoracic surgery, lung
cancer, smoking history, American Society of Anesthesiologists class,
and Eastern Clinical Oncology Group/Zubrod score. Related health status
indicators in the NETT included the Quality of Well-Being Score and the
St George’s Respiratory Questionnaire score; the Quality of Well-Being
score, which ranges from 0 to 1, with higher values indicating better
health-related quality of life;15 and St George’s Respiratory Questionnaire
score, which ranges from 0 to 100, with lower values indicating better
health-related quality of life.16
Outcomes within 30 days of surgery were compared between
patients in the STS Database and non–high-risk subjects in the NETT.
These outcomes included readmission to the intensive care unit,
sepsis, arrhythmia requiring treatment, myocardial infarction, ventilator
dependence beyond 48 hours postoperatively, and reintubation. Mortality
within 30 days of surgery was compared between patients in the STS
Database and (1) all subjects in the NETT, (2) the non–high-risk NETT
subset, and (3) the NETT subset with upper lobe predominant disease
and low exercise tolerance.gery c December 2014
FIGURE 1. Yearly annual volume of LVRS reported in the STSDatabase from January 2003 to December 2010; 2011 volume is not shown, because yearly
data were incomplete at the time of this study. LVRS, Lung volume reduction surgery.
TABLE 1. Quantitative comparison of preoperative and operative
characteristics of patients undergoing lung volume reduction surgery
in the National Emphysema Treatment Trial versus the Society of
Thoracic Surgeons Database
Characteristics
STS NETT Mean difference
P value*Mean Mean Mean jDj (95% CI)
Age, mean y 61.3 66.5 5.2 (6.1 to 4.3) <.001
Sex .192
Male 54.6% 58.4% 3.7% (9.4 to 1.9)
Female 45.4% 41.6% 3.7% (1.9 to 9.4)
Race .010
White 91.4% 95.6% 4.1% (6.9 to 9.7)
Black 5.1% 3.1% 1.9% (0.3 to 4.2)
Other 3.5% 1.3% 2.2% (0.4-3.9)
Pulmonary function tests
FEV1% predicted 31.1% 28.1% 3.0% (1.6-4.4) <.001
DLCO% predicted 37.8% 29.2% 8.6% (6.9-10.2) <.001
Surgical approach <.001
Median sternotomy 35.8% 70.0% 34.2% (40.2 to 28.1)
VATS 51.3% 30.0% 21.3% (15.1-27.5)
Other 12.9% 0% 12.9% (9.6-16.3)
CI, Confidence interval; DLCO, carbon monoxide diffusing capacity; FEV1, forced
expiratory volume in 1 second; NETT, National Emphysema Treatment Trial; STS,
Society of Thoracic Surgeons; VATS, video-assisted thoracic surgery. *P values
calculated using 2-sided t tests for continuous variables and chi-square tests for dif-
ferences in proportions.
Decker et al General Thoracic Surgery
G
T
SIn all analyses, missing observations in STS data were excluded from
the denominator; however, patients with missing data were not excluded
from the overall STS cohort. Only deidentified aggregate data were avail-
able from the STS Database; therefore, imputation could not be performed.
Proportions of missing observations were reported with outcomes to aid
interpretation. In addition, to account for missing data, mortality outcomes
were analyzed under 2 other scenarios: one in which all missing patients
were assumed to be alive and another in which all missing patients were
assumed to be deceased. Statistical analyses were performed in STATA
(StataCorp 2011. Stata Statistical Software: Release 12. StataCorp LP,
College Station, Tex).
RESULTS
From January 2003 to June 2011, 585 patients underwent
LVRS reported in the STS Database. The yearly annual vol-
ume of LVRS is shown in Figure 1. Patients in the STS
Database were compared with the 608 NETT subjects
who were randomized to surgery, of whom 538 were
determined to be non–high risk and 139 had upper lobe
predominant disease and low exercise tolerance.
When the preoperative characteristics of patients in the
STS Database were compared with those of all NETT sub-
jects, STS subjects were younger and a larger proportion
was of a nonwhite race (Table 1). There were no patients
in the STS Database with forced expiratory volume in 1 sec-
ond or carbon monoxide diffusing capacity less than 20%
of predicted, who would fall into the high-risk category
deemed by the NETT. Although the majority of NETT sub-
jects underwent LVRS via a median sternotomy approach,
most STS subjects underwent the procedure with a
thoracoscopic approach. Other approaches included cervi-
cal, subxiphoid, thoracotomy, and transverse sternotomy.The Journal of Thoracic and CarOverall, less than half of patients in the STSDatabase had
major comorbidities (Table 2). Approximately 10% of
patients in the STS Database had previous cardiothoracic
surgery, whereas NETT enrollees with previous sternotomy
or lobectomy were excluded. Some 1.5% of patients in the
STS Database had a diagnosis of lung cancer, whereas thediovascular Surgery c Volume 148, Number 6 2653
TABLE 2. Description of preoperative health status of patients undergoing lung volume reduction surgery in the Society of Thoracic Surgeons
Database compared with the National Emphysema Treatment Trial selected cohort
Patient characteristics STS% NETT*
Comorbidities
CHF 2.6 Excluded if ‘‘Congestive heart failure within 6 mo of interview and ejection fraction
<45%’’
Coronary artery disease 17.4
Pulmonary hypertension 0.7 Excluded if ‘‘Pulmonary hypertension: mean PPA on right heart catheterization 35
mm Hg (38 mm Hg in Denver) or peak systolic PPA on right heart
catheterization 45 mm Hg (50 mm Hg in Denver); right heart catheterization
is required to rule out pulmonary hypertension if peak systolic PPA on
echocardiogram>45 mm Hg’’
Systemic hypertension 45.1 Excluded if ‘‘Uncontrolled hypertension (systolic>200 mm Hg or diastolic>110
mm Hg)’’
Peripheral vascular disease 2.6
Diabetes 9.4
Steroids 17.8 Excluded if ‘‘Daily use of more than 20 mg of prednisone or its equivalent as of
randomization’’
Previous cardiothoracic surgery 9.9 Excluded if ‘‘Previous sternotomy or lobectomy’’
Lung cancer 1.5 Excluded if ‘‘Evidence of systemic disease or neoplasia that is expected to
compromise survival over the duration of the trial’’ or ‘‘Pulmonary nodule
requiring surgery’’
Preoperative chemotherapy and radiation 1.0
Smoking history Included if ‘‘Nonsmoker (tobacco products) for 4 mo before initial interview and
patient remains a nonsmoker throughout screening (by history)’’Current smoker 4.6
Quit within 1 y previously 8.4
Quit>1 y ago 52.5
Never smoked 34.5
ASA class Surgical Patients’ average daily Quality of Well-Being score:y
0.58  0.12
Upper Lobe Predominant, Low Exercise Tolerant Quality of Well-Being score:
0.57  0.12
Surgical Patients’ St George’s Respiratory Questionnaire Score:z
52.5  12.6
Upper Lobe Predominant, Low Exercise Tolerant St George’s Respiratory
Questionnaire Score:
54.3  12.1
I 2.0
II 6.8
III 63.1
IV 28.0
V 0.2
ECOG/Zubrod score
0, normal activity 9.1
1, symptomatic but ambulatory 63.1
2, symptomatic,<50% daytime in bed 20.4
3, symptomatic,>50%<100% daytime in bed 4.5
4, bedridden 2.9
ASA, American Society of Anesthesiologists;ECOG, Eastern Clinical Oncology Group;CHF, congestive heart failure;NETT, National Emphysema Treatment Trial; STS, Society
of Thoracic Surgeons; PPA, pulmonary arterial pressure. *Referenced from Fishman and colleagues
4 (Appendix Table E1). yQuality of Well-Being score is on a scale from 0 to 1,
with higher scores indicating better health. zSt George’s Respiratory Questionnaire score is on a scale from 0 to 100, with lower scores indicating better health.
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SNETT excluded enrollees with pulmonary nodules or
evidence of neoplasia that could interfere with the trial.
The majority of patients in the STS Database had
American Society of Anesthesiologists class III or IV and
Eastern Clinical Oncology Group or Zubrod scores of 1
or 2, indicating that most patients were symptomatic and
ambulatory or partially disabled. This parallels with the
middle-range health-related quality of life scores reported
by NETT subjects (Table 2).
The median time from surgery to evaluation of 30-day
outcomes was 0.7 month in all NETT subjects, including
the non–high-risk subset and 0.8 month in the subset with
upper lobe predominant disease and low exercise toler-
ance.4 Outcomes were assessed at 30 days postoperatively2654 The Journal of Thoracic and Cardiovascular Surin the STS Database. Given the slight difference in time
from surgery to evaluation of outcomes in NETT versus
the STS Database, mortality within 60 days is reported for
NETT subjects as a frame of reference.
Mortality within 30 days of LVRS was not significantly
different between STS subjects and all NETT subjects
(Table 3). When 30-day mortality rates were compared be-
tween STS subjects and the non–high-risk NETT subset
(Table 4), as well as the NETT subset with upper lobe pre-
dominant disease and low exercise tolerance (Table 5), STS
subjects had a 3% to 4% higher mortality rate that was
statistically significant. Mortality assessed at 1.7 months
postoperatively was 4.8% among non–high-risk NETT
subjects and 2.9% among subjects with upper lobegery c December 2014
TABLE 3. Comparison of outcomes after lung volume reduction
surgery in Society of Thoracic Surgeons Database versus National
Emphysema Treatment Trial
Outcomes STS*% All NETT%
Difference
P valuey% jDj (95% CI)
30-d mortalityz 5.6 3.6 2.0 (0.5 to 4.5) .113
CI, Confidence interval; NETT, National Emphysema Treatment Trial; STS, Society
of Thoracic Surgeons. *Missing STS observations excluded. yP values from chi-
square tests. zReferenced from Fishman and colleagues.4
TABLE 5. Comparison of outcomes after lung volume reduction
surgery in Society of Thoracic Surgeons Database versus National
Emphysema Treatment Trial subset with upper-lobe predominant
disease and low exercise tolerance
Outcomes STS*%
NETT, upper
lobe disease Yexercise
tolerance%
Difference
P valuey% jDj (95% CI)
30-d mortalityz 5.6 1.4 4.2 (1.4-7.0) .039
CI, Confidence interval; NETT, National Emphysema Treatment Trial; STS, Society
of Thoracic Surgeons. *Missing STS observations excluded. yP values from
chi-square tests. zReferenced from Fishman and colleagues.4
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Spredominant disease and low exercise tolerance, compared
with the STS 30-day mortality rate of 5.6%.
When other outcomes were compared between STS sub-
jects and non–high-risk NETT subjects randomized to sur-
gery, there were no significant differences in rates of
intensive care unit readmission, sepsis, arrhythmia
requiring treatment, or myocardial infarction (Table 4).
STS subjects had significantly lower rates of ventilator
dependence lasting more than 48 hours postoperatively
and reintubation.
Mortality data were missing for 83 (14%) of the patients
in the STS Database. There were 213 to 214 (36%-37%)
missing observations for each of the other outcome vari-
ables; missing observations were excluded from sample
proportions. When all missing patients were assumed to
be alive, rather than excluded, no significant differences
in mortality were identified between patients undergoing
LVRS in the STS Database versus the NETT (Appendix
Tables E1 and E2). Mortality rates were significantly
higher for patients undergoing LVRS in the STS Database
compared with those in the NETT when all missing
patients were assumed to be deceased (Appendix Tables
E3 and E4).DISCUSSION
This study of LVRS in the STS Database from 2003 to
2011 is the first longitudinal, population-level assessmentTABLE 4. Comparison of outcomes after lung volume reduction
surgery in Society of Thoracic Surgeons Database versus non–high-
risk National Emphysema Treatment Trial subset
Outcomes STS*%
Non–high-risk
NETT subset%
Difference
P valuey% jDj (95% CI)
30-d mortalityz 5.6 2.2 3.4 (1.0-5.0) .005
Readmittance
to ICUx
7.8 11.7 3.9 (8.8 to 1.0) .156
Sepsisx 1.9 2.5 0.6 (2.5 to 1.3) .544
Arrhythmiax 16.2 18.6 2.4 (7.5 to 2.6) .350
MIx 1.1 1.0 0.1 (1.3 to 1.4) .910
Ventilator>48 hx 4.6 13.6 9.1 (12.7 to 5.4) <.001
Reintubationx 12.9 21.8 8.9 (13.8 to 3.9) <.001
CI, Confidence interval; ICU, intensive care unit; MI, myocardial infarction; NETT,
National Emphysema Treatment Trial; STS, Society of Thoracic Surgeons. *Missing
STS observations excluded. yP values from chi-square tests. zReferenced from Fish-
man and colleagues.4 xReferenced from Naunheim and colleagues.13
The Journal of Thoracic and Carof LVRS since the NETT. Our study demonstrates that since
the NETTwas published in 2003, surgeons have performed
LVRS for a broader group of patients (including smokers,
younger patients, and people with previous cardiac sur-
gery); techniques have evolved (with greater use of thoraco-
scopic surgery); and outcomes differ in some areas while
remaining the same in others.
The annual volume of LVRS in the STS Database
increased substantially from 2003 to 2004 but did not
steadily increase thereafter. This suggests that LVRS is un-
derused, as reported in a study of Medicare claims from
2004 to 2005 in which there were only 258 claims for
LVRS over 21 months.10 When considering that emphy-
sema is reported to affect 4.7 million Americans,2 it appears
that only a small proportion of these patients are pursuing
LVRS as a treatment option. Reasons for this remain un-
clear. Overly restrictive patient selection criteria do not
appear to be the cause. Overall differences in patient char-
acteristics between the STS Database and the NETT
demonstrate that patient selection was less restrictive in
the STS Database. With underuse unlikely to be related to
restrictive selection criteria, it may instead be related to
restrictive referral patterns and limited access to this
specialized surgery.
When compared with subjects in the NETT, more sub-
jects in the STS Database underwent LVRS via a thoraco-
scopic approach, which is likely a consequence of an
increase in surgeons’ comfort with thoracoscopy and
video-assisted thoracoscopic surgery.17 The fact that 10%
of patients in the STS Database had previous cardiothoracic
surgery is a testament to surgeons’ increased comfort with
the technical aspects of the lung volume reduction proce-
dure. The younger mean age of STS subjects may relate
to increasing numbers of insurers offering coverage of
LVRS,18,19 following the Centers for Medicare &
Medicaid Services (CMS) published criteria for expanded
coverage of LVRS in 2003.20 However, the CMS has
restricted the types of facilities that are eligible for reim-
bursement of LVRS to those approved for the NETT,
credentialed by the Joint Commission on Accreditation of
Healthcare Organizations under their Disease Specific Cer-
tification Program for LVRS, and those approved by Medi-
care for lung or heart and lung transplants.21 Although thisdiovascular Surgery c Volume 148, Number 6 2655
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Spolicy maintains the quality of LVRS by requiring that the
appropriate infrastructure is in place, it likely restricts ac-
cess to this surgery that could benefit more than 1 million
Americans. To address underuse of LVRS, perhaps an in-
crease in the number of healthcare teams dedicated to treat-
ment of advanced pulmonary disease is needed, similar to
but distinct from healthcare teams dedicated to heart and
lung transplantation or thoracic oncology.
In this study, 1.5% of patients in the STS Database were
reported to have lung cancer. This may have been a result of
miscoding of the surgical procedure as a lung volume
reduction rather than a cancer resection, but the surgery
also may have been performed for the dual purpose of
lung volume reduction and cancer resection, as previously
published.22 Coding errors are always possible when col-
lecting administrative data. However, given the stringent re-
porting requirements for reimbursement of LVRS,18-21
there is a low likelihood that coding errors would be
frequent enough to skew the results in our large sample
size of more than 500 patients.
Outcomes after LVRS were similar between the STS
Database and the NETT, with key exceptions. Lower rates
of reintubation and prolonged ventilation in the STS Data-
base may be related to nationwide efforts to improve these
outcomes over the past decade. The STS, the American Col-
lege of Surgeons-National Surgical Quality Improvement
Program,23 and the Physician Quality Reporting System
in conjunction with CMS24 use reintubation and prolonged
ventilation as healthcare quality indicators. Hospitals
throughout the country have developed quality-
improvement programs to address these indicators, with
increasing success.25,26
Analysis of outcomes further demonstrated that patients
in the STS Database had a similar 30-day mortality rate
when compared with all NETT subjects, but when
compared with non–high-risk NETT subjects and those
with upper lobe predominant disease and low exercise
tolerance, STS subjects had a higher mortality rate. This
may be related to differences in patient selection or surgi-
cal care outside of a clinical trial. Given that 30-day mor-
tality has been demonstrated to be higher in patients
undergoing bilateral resection, compared with unilateral
resection,27 the inclusion of patients in the STS Database
who underwent unilateral LVRS was expected to have
skewed the 30-day mortality rate in the STS Database to
a rate lower than reported in the NETT; however, this
was not the case.
As public attention to quality reporting increases and
pay-for-performance policies are increasingly imple-
mented, thoracic surgeons may be compelled to decide on
thresholds for mortality. It may be unreasonable to expect
the outcomes in practice to be as good as the best subgroup
of outcomes in a randomized controlled clinical trial, but it
is reasonable to expect a certain standard of care and decide2656 The Journal of Thoracic and Cardiovascular Suron a threshold at which mortality risk cannot outweigh po-
tential benefits.
This study measured outcomes with respect to an abso-
lute benchmark set by the NETT. Current pay-for-
performance models are based on both absolute and relative
performance measurements.28 Therefore, future investiga-
tion of relative performance measurements for LVRS would
allow hospitals to compare their performance with others
and potentially learn from high-performing outliers’ patient
selection, follow-up care, and other potential determinants
of quality.
Although the less-restrictive patient selection demon-
strated in the STS cohort may contribute to the higher mor-
tality rate when compared with the selected NETT subjects,
a small difference in mortality rates may not warrant re-
stricting marginal non–high-risk candidates from access
to this potentially life-saving procedure that has been shown
to provide substantial improvements in quality of life.4-9
Study Limitations
It is worth mentioning that the mortality rates reported in
the NETT were captured under a slightly narrower time
window (0.7 month in all NETT subjects including the
non–high-risk subset and 0.8 month in the upper lobe pre-
dominant low exercise tolerant subset) compared with the
30-day mortality in the STS Database. Given that the
non–high-risk NETT subset mortality rates at 1.7 months
remained below the STS 30-day mortality rate, it is unlikely
that the 3% to 4% difference in mortality rates can be
wholly attributed to the difference in time windows.
Although there were differences in data collection between
the STS Database and the NETT, as described, comparison
remains informative with this limitation in mind.
This study also was limited by a lack of long-term data on
outcomes of patients in the STS Database. Although 30-day
outcomes were useful for assessing quality of care in
the short term, previous studies have shown that the
measurement of survival benefits and improvement in
quality-adjusted life after LVRS requires long-term data
collection.5,9 Measurement of 90-day and 1-year outcomes
after LVRS in quality-assessment databases such as that of
the STS would facilitate future studies. This study of the
STS Database also was limited by missing data, which
comprised 14% to 37% of observations. Results should
be interpreted while considering the proportion of missing
observations (Appendix Table E1). Overall, the limitations
of this study were largely due to limitations of observational
data. The STS Database provides a national sample that is
likely to be biased toward higher participation by major ac-
ademic centers and hospitals with sufficient data-collection
resources. This study was not designed to capture total na-
tional LVRS volume in the United States or to prescribe pol-
icy to address LVRS quality. Rather, the study was designed
to provide a description that facilitates further investigationgery c December 2014
Decker et al General Thoracic Surgeryinto quality assessment and quality assurance for LVRS. As
we have demonstrated, this goal was achieved, and the STS
Database proved to be useful in providing an unadjusted
assessment of volume and outcomes for LVRS.
Keeping thoracic surgeons apprised of unadjusted quality
assessments is essential to involving surgeons in the identi-
fication of surgery-specific determinants of quality, the
development of surgery-specific quality measures, and
therefore the evolution of quality-improvement databases
such as that of the STS. This study highlights the need to
invest in future analyses that identify determinants of out-
comes after LVRS so that future quality assessments can
adjust for patient characteristics, payer status, location,
and so forth. This is an iterative process that is best conduct-
ed with surgeons’ involvement.G
T
SCONCLUSIONS
Overall, the major findings of this study demonstrate that
mortality rates are higher in the STSDatabase than theywere
in selected NETT subjects and about the same compared
with the overall NETT LVRS arm. Interpretation of differ-
ences in mortality rates is complicated by lack of consensus
on appropriate benchmarks for mortality rates after LVRS.
Our results and conclusions, like those of any observational
study, are limited to description and interpretation of the
available data. We maintain that the STS Database provides
a geographically diverse national sample of outcomes after
LVRS that may capture national trends. This study demon-
strates the importance of patient selection and the need to
develop consensus on appropriate benchmarks for morbidity
and mortality rates after LVRS. Our study also underscores
the need for primary care providers, pulmonologists, and
thoracic surgeons to address the heavy burden of chronic
lower respiratory disease in the United States by more
frequently engaging a multidisciplinary team in discussions
with patients regarding the treatment options for emphy-
sema, taking into consideration individual patient risk factors
and weighing risks and benefits in an evidence-based
fashion. More dedicated centers for treatment of advanced
respiratory disease are needed to improve access to LVRS,
while refining preoperative evaluation and postoperative
management of emphysema in a coordinated way.References
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APPENDIX TABLE E1. Comparison of outcomes after lung volume
reduction surgery in Society of Thoracic Surgeons Database versus
National Emphysema Treatment Trial: Missing patients in the
Society of Thoracic Surgeons Database assumed to be alive
Outcomes STS*% All NETT%
Difference
P valuey% jDj (95% CI)
30-d mortalityz 4.8 3.6 1.2 (0.1 to 3.5) .306
CI, Confidence interval; NETT, National Emphysema Treatment Trial; STS, Society
of Thoracic Surgeons. *Missing STS observations excluded. yP values from chi-
square tests. zReferenced from Fishman and colleagues.4
APPENDIX TABLE E2. Comparison of outcomes after lung volume
reduction surgery in Society of Thoracic Surgeons Database versus
National Emphysema Treatment Trial subjects with upper-lobe
predominant disease and low exercise tolerance: Missing Society of
Thoracic Surgeons subjects assumed to be alive
Outcomes STS*%
NETT, upper
lobe disease Yexercise
tolerance%
Difference
P valuey% jDj (95% CI)
30-d mortalityz 4.8 1.4 3.4 (0.8-6.0) .072
CI, Confidence interval; NETT, National Emphysema Treatment Trial; STS, Society
of Thoracic Surgeons. *Missing STS observations excluded. yP values from
chi-square tests. zReferenced from Fishman and colleagues.4
APPENDIX TABLE E3. Comparison of outcomes after lung volume
reduction surgery in Society of Thoracic Surgeons Database versus
National Emphysema Treatment Trial: Missing Society of Thoracic
Surgeons subjects assumed to be deceased
Outcomes STS*% All NETT%
Difference
P valuey% jDj (95% CI)
30-d mortalityz 19.0 3.6 15.4 (11.9-18.9) <.001
CI, Confidence interval; NETT, National Emphysema Treatment Trial; STS, Society
of Thoracic Surgeons. *Missing STS observations excluded. yP values from chi-
square tests. zReferenced from Fishman and colleagues.4
APPENDIX TABLE E4. Comparison of outcomes after lung volume
reduction surgery in Society of Thoracic Surgeons Database versus
National Emphysema Treatment Trial subjects with upper-lobe
predominant disease and low exercise tolerance: Missing Society of
Thoracic Surgeons subjects assumed to be deceased
Outcomes STS*%
NETT, upper
lobe disease Yexercise
tolerance%
Difference
P valuey% jDj (95% CI)
30-d mortalityz 19.0 1.4 17.6 (13.8-21.3) <.001
CI, Confidence interval; NETT, National Emphysema Treatment Trial; STS, Society
of Thoracic Surgeons. *Missing STS observations excluded. yP values from chi-
square tests. zReferenced from Fishman and colleagues.4
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